



Cambridge Healthtech Institute Announces Molecular Med Tri-Conference 2014 Short Courses

Twenty 3-hour short courses to be held at the 21st International Tri-Conference.

NEEDHAM, MA, USA, October 15, 2013 /EINPresswire.com/ -- Cambridge Healthtech Institute announces the short course lineup at the 21st International [Molecular Medicine Tri-Conference](#), taking place February 9-10, 2014 at the Moscone North Convention Center in San Francisco, CA.

The twenty scheduled short courses will cover a variety of diagnostics, informatics, clinical, and cancer-related topics and will include presentations from groups including Genentech, XIFIN, Golden Helix, OptumInsight, Illumina, MD Anderson Cancer Center, SAIC-Frederick, Stanford University and more.

Sunday, February 9 | 2:00 - 5:00PM (<http://bit.ly/18uJs7Y>)

- CTCs from Bench to Bed: Streamlining from Research to Clinical Practice
- Latest Advances in Molecular Pathology
- Starting an NGS Lab Part I: Technical Considerations
- Sequencing 101
- Best Practices in Personalized and Translational Medicine
- PCR Part I: qPCR and High Resolution Melting in Molecular Diagnostics
- Maximizing Reimbursement and How Coding Changes have Impacted a Complex Diagnostic Landscape

Sunday, February 9 | 5:30 - 8:30PM (<http://bit.ly/18uJs7Y>)

- Starting an NGS Lab Part II: Practical and Business Aspects
- NGS Assembly and Alignment
- PCR Part II: Digital PCR Applications and Advances
- Regulatory Compliance in Drug-Diagnostics Co-Development
- Building an Investigational Program to Establish the Clinical Value of a Test

Monday, February 10 | 8:30 - 11:30AM (<http://bit.ly/18uJs7Y>)

- Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace

- Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
- Systems Biology: A Molecular Nutrition Perspective
- Neuro-Innovation
- Isolation and Characterization of Cancer Stem Cells
- The Next Frontier in Sample Shipping for Molecular Infectious Disease Testing: Eliminate Dry Ice
- Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations
- Ethical, Legal, and Social Issues Related to Human Specimen Research

For more information about the Tri-Conference and to register, visit <http://bit.ly/18ujs7Y>

About Cambridge Healthtech Institute (<http://www.healthtech.com>)

CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI's Media Group, which includes news websites and e-newsletters including Bio-IT World and Clinical Informatics News.

About Molecular Med Tri-Conference (<http://www.triconference.com>)

The 21st International Molecular Medicine Tri-Conference is the industry's Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology. Spanning six days this year, the Tri-Conference includes an expanded program that includes 6 symposia, over 20 short courses, and 15 main programs. For the first time in over 10 years we're bringing back a dedicated conference on sequencing. As many will recall this event's infancy was heavily devoted to the Human Genome Project and we are excited to reintroduce sequencing to this event.

Lisa Scimemi

Cambridge Healthtech Institute

781-972-5444

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/171468088>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.